ホルモン避妊薬市場規模、シェア、成長分析、製品別、ホルモン別、年齢別、エンドユーザー別、地域別 - 産業予測、2025-2032年

ホルモン避妊薬の世界市場規模は、2023年に193億米ドルと評価され、2024年の201億1,000万米ドルから2032年には279億5,000万米ドルに成長し、予測期間中（2025年～2032年）のCAGRは4.2％で成長する見通しです。

世界のホルモン避妊薬市場は大幅な成長が見込まれており、2022年から2030年にかけてCAGR約4.5％で拡大すると予測されています。この成長には、避妊法に対する認識と受容の高まり、性感染症（STI）の罹患率の上昇、効果的な家族計画ソリューションに対する需要の高まりが大きく寄与しています。経口避妊薬は、その有効性と利便性により、特にエストロゲンとプロゲスチンの両方を含む配合ピルが市場を独占しています。しかし、プロゲスチンのみのピルは、エストロゲンを使用できない女性にとって理想的であり、副作用が少ないことから、今後成長が加速すると予想され、支持を集めています。STIの予防には限界があるため、コンドームの同時使用は依然として重要です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

ホルモン避妊薬市場規模：製品別

• 市場概要
• 経口避妊薬
• 注射による避妊
• 緊急避妊薬
• 膣リング
• 経皮パッチ

ホルモン避妊薬市場規模：ホルモン別

• 市場概要
• プロゲスチンのみの避妊薬
• 組み合わせたホルモン避妊薬

ホルモン避妊薬市場規模：年齢別

• 市場概要
• 15～24歳
• 25～34歳
• 35～44歳
• 44歳以上

ホルモン避妊薬市場規模：エンドユーザー別

• 市場概要
• 病院
• 家庭用
• クリニック

ホルモン避妊薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Bayer AG（Germany）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan N.V.（USA）
• Viatris Inc.（USA）
• Organon & Co.（USA）
• Mithra Pharmaceuticals（Belgium）
• Agile Therapeutics, Inc.（USA）
• Mayne Pharma Group Limited（Australia）
• Afaxys, Inc.（USA）
• Pregna International Ltd.（India）
• Lupin Pharmaceuticals Inc.（India）
• Cipla Limited（India）
• Sun Pharmaceutical Industries Limited（India）
• Piramal Enterprises Limited（India）

結論と推奨事項

Global Hormonal Contraceptive Market size was valued at USD 19.3 billion in 2023 and is poised to grow from USD 20.11 billion in 2024 to USD 27.95 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global hormonal contraceptive market is poised for significant growth, projected to expand at a compound annual growth rate (CAGR) of around 4.5% between 2022 and 2030. This growth is largely fueled by increasing awareness and acceptance of contraceptive methods, a rising incidence of sexually transmitted infections (STIs), and heightened demand for effective family planning solutions. Oral contraceptives dominate the market, particularly combination pills that contain both estrogen and progestin, thanks to their effectiveness and convenience. However, progestin-only pills are gaining traction, anticipated to grow faster due to their minimal side effects, making them ideal for women who cannot use estrogen. Given their limitations in preventing STIs, the concurrent use of condoms remains crucial for protection.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segmental Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

A significant driver of the global hormonal contraceptive market is the rising awareness and acceptance of contraception for family planning purposes. As population levels continue to surge, especially in developing nations, there is an escalating demand for reliable birth control solutions that enable couples to control family size and spacing effectively. This growing recognition of the importance of contraception has resulted in a notable uptick in the utilization of hormonal contraceptives, which are celebrated for their high efficacy in preventing unintended pregnancies while providing a user-friendly and reversible option for individuals seeking to manage their reproductive health.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable constraints due to various social and cultural factors that hinder women's access to contraceptive methods. In numerous cultures and communities, contraception is often stigmatized, and certain religious doctrines explicitly forbid its use. Furthermore, a significant lack of awareness and education surrounding contraceptive options exists in many areas globally, contributing to diminished demand for such products. These intertwined social and cultural influences can significantly impede market growth, particularly in regions where such factors heavily influence the choices regarding contraceptive usage. Addressing these challenges is crucial for expanding access to hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a pronounced shift towards Long-Acting Reversible Contraceptives (LARCs), such as intrauterine devices (IUDs) and subdermal implants, reflecting a significant trend among consumers. These methods offer high efficacy in preventing unintended pregnancies while providing extended duration of use, appealing particularly to younger women and those desiring reliable, low-maintenance contraception. This growing preference is driven by increasing awareness of reproductive health options, enhanced convenience, and the desire for a hassle-free experience. As a result, LARCs are rapidly gaining traction, reshaping the landscape of hormonal contraceptive solutions worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2025-2032)

• Market Overview
• Oral Contraceptive Pills
• Injectable Birth Control
• Emergency Contraceptive Pills
• Vaginal Rings
• Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2025-2032)

• Market Overview
• Progestin Only Contraceptive
• Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2025-2032)

• Market Overview
• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Household
• Clinics

Global Hormonal Contraceptive Market Size & CAGR (2025-2032)

• North America (Product, Hormones, End User, Age)
  • US
  • Canada
• Europe (Product, Hormones, End User, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Hormones, End User, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Hormones, End User, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Hormones, End User, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pregna International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations